Anne Dørum
Position: Senior consultant, MD, PhD
Phone: +47 22 93 44 25

Download CV (in Word format)


Author network for Anne Dørum by COREMINE medical

Publications 2017

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2017)
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
BMC Cancer, 17 (1), 97
PubMed 28158999

Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R (2017)
TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch, 470 (6), 665-678
PubMed 28432432

Johansen N, Liavaag AH, Iversen OE, Dørum A, Braaten T, Michelsen TM (2017)
Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
Acta Obstet Gynecol Scand, 96 (5), 547-555
PubMed 28236297

Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G (2017)
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Br J Cancer, 116 (4), 455-463
PubMed 28118323

Publications 2016

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S (2016)
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
Tumour Biol, 37 (8), 10697-702
PubMed 26867771

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J et al. (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
N Engl J Med, 375 (22), 2154-2164
PubMed 27717299

Publications 2015

Bjørnslett M, Dahl AA, Sørebø Ø, Dørum A (2015)
Psychological distress related to BRCA testing in ovarian cancer patients
Fam Cancer, 14 (4), 495-504
PubMed 25980896

Publications 2012

Bjørnslett M, Knappskog S, Lønning PE, Dørum A (2012)
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
BMC Cancer, 12, 454
PubMed 23039163

Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E, Norwegian Breast Cancer Group trial NBCG VI, Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE (2012)
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
PLoS One, 7 (4), e36263
PubMed 22558411

Michelsen TM, Dørum A, Cvancarova M, Liavaag AH, Dahl AA (2012)
Association between hysterectomy with ovarian preservation and cardiovascular disease in a Norwegian population-based sample
Gynecol Obstet Invest, 75 (1), 61-7
PubMed 23220872

Publications 2011

Dahl AA, Gudbergsson SB, Dørum A, Fosså SD, Liavaag AH, Sørebø Ø (2011)
"The impact of cancer scale" version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors
Qual Life Res, 21 (8), 1459-70
PubMed 22045155

Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS et al. (2011)
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
Cancer Cell, 19 (2), 273-82
PubMed 21316605

Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E, Gynecologic Cancer Intergroup (2011)
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
Ann Oncol, 22 (11), 2417-23
PubMed 21402619

Publications 2010

Michelsen TM, Tonstad S, Pripp AH, Tropé CG, Dørum A (2010)
Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer
Int J Gynecol Cancer, 20 (2), 233-9
PubMed 20169665

Publications 2009

Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2009)
Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors
BMC Cancer, 9, 2
PubMed 19121203

Liavaag AH, Tonstad S, Pripp AH, Tropé C, Dørum A (2009)
Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study
Int J Gynecol Cancer, 19 (4), 634-40
PubMed 19509562

Michelsen TM, Dørum A, Dahl AA (2009)
A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer
Gynecol Oncol, 113 (1), 128-33
PubMed 19178933

Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA (2009)
Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer
Int J Gynecol Cancer, 19 (6), 1029-36
PubMed 19820364

Publications 2008

Dørum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA (2008)
Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2)
Gynecol Oncol, 109 (3), 377-83
PubMed 18407340

Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P (2008)
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers
J Med Genet, 46 (9), 593-7
PubMed 18413372

Michelsen TM, Pripp AH, Tonstad S, Tropé CG, Dørum A (2008)
Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study
Eur J Cancer, 45 (1), 82-9
PubMed 19008092

Publications 2007

Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C, Dahl AA (2007)
A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach
Gynecol Oncol, 108 (2), 348-54
PubMed 17996925

Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2007)
Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?
J Clin Oncol, 25 (15), 2049-56
PubMed 17513809

Publications 2006

Aghmesheh M, Suo Z, Friedlander M, Nesland JM, Kaern J, Stewart M, Kconfab, Dorum A, Tucker KM, Buckley MF (2006)
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas
Pathology, 38 (2), 145-51
PubMed 16680901

Knudsen A, Monstad SE, Dørum A, Lønning PE, Salvesen HB, Drivsholm L, Aarseth JH, Vedeler CA (2006)
Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
Cancer Immunol Immunother, 55 (10), 1280-4
PubMed 16429314

Monstad SE, Storstein A, Dørum A, Knudsen A, Lønning PE, Salvesen HB, Aarseth JH, Vedeler CA (2006)
Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique
Clin Exp Immunol, 144 (1), 53-8
PubMed 16542365

Sert B, Abeler VM, Dørum A, Trope CG (2006)
A new approach to treatment of early-stage cervical carcinoma: entire laparoscopic abdominal radical hysterectomy with bilateral pelvic lymphadenectomy without vaginal cuff closure--case reports
Eur J Gynaecol Oncol, 27 (5), 513-8
PubMed 17139990

Publications 2005

Davidson B, Xi Z, Klokk TI, Tropé CG, Dørum A, Scheistrøen M, Saatcioglu F (2005)
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
Am J Clin Pathol, 123 (3), 360-8
PubMed 15716231

Dørum A, Blom GP, Ekerhovd E, Granberg S (2005)
Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study
Am J Obstet Gynecol, 192 (1), 48-54
PubMed 15672002

Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A (2005)
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
BMC Cancer, 5, 134
PubMed 16229746

Publications 2004

Aghmesheh M, Nesland JM, Kaern J, Dorum A, Edwards L, Byth K, Friedlander M, Jackson P, Tucker KM, Russell PJ (2004)
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers
Gynecol Oncol, 95 (3), 430-6
PubMed 15581943

Bjørge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, Langseth H, Nustad K, Tropé CG, Dørum A (2004)
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study
Br J Cancer, 91 (10), 1829-34
PubMed 15477862

Ekstrøm PO, Bjørge T, Dørum A, Longva AS, Heintz KM, Warren DJ, Hansen S, Gislefoss RE, Hovig E (2004)
Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis
Anal Chem, 76 (15), 4406-9
PubMed 15283579

Publications 2000

Bjørge T, Dørum A, Tropé CG (2000)
[Screening for ovarian cancer]
Tidsskr Nor Laegeforen, 120 (12), 1444-8
PubMed 10851943

Publications 1999

Borg A, Dørum A, Heimdal K, Maehle L, Hovig E, Møller P (1999)
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations
Dis Markers, 15 (1-3), 79-84
PubMed 10595257

Dørum A, Heimdal K, Hovig E, Inganäs M, Møller P (1999)
Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer
Am J Hum Genet, 65 (3), 671-9
PubMed 10441573

Dørum A, Heimdal K, Løvslett K, Kristensen G, Hansen LJ, Sandvei R, Schiefloe A, Hagen B, Himmelmann A, Jerve F, Shetelig K, Fjaerestad I, Tropé C, Møller P (1999)
Prospectively detected cancer in familial breast/ovarian cancer screening
Acta Obstet Gynecol Scand, 78 (10), 906-11
PubMed 10577622

Dørum A, Hovig E, Tropé C, Inganas M, Møller P (1999)
Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA
Eur J Cancer, 35 (5), 779-81
PubMed 10505039

Heimdal K, Apold J, Maehle L, Dørum A, Møller P (1999)
[Hereditary breast cancer in Norway]
Tidsskr Nor Laegeforen, 119 (26), 3929-32
PubMed 10592755

Publications 1998

Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjaerg L, Dørum A, Møller P, Weber BL, Børresen-Dale AL (1998)
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening
Hum Mutat, 11 (2), 166-74
PubMed 9482581

Dørum A, Heimdal K, Møller P (1998)
Clinical implications of BRCA1 genetic testing
Acta Obstet Gynecol Scand, 77 (4), 458-61
PubMed 9598958

Moller P, Maehle L, Heimdal K, Dorum A, Apold J, Engebretsen LF, Kaurin RM, Jorgensen OG, Helgerud P, Qvist H, Bjorndal H, Kullmann G, Bohler P, Nysted A, Soreide JA, Varhaug JE, Aas T, Fjosne HE, Hagen A, Due J, Karesen R, Formoe E, Malme PA, Stedjeberg JO, Svenningsen SS et al. (1998)
Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer
Breast, 7 (1), 55-59

Narod SA, Risch H, Moslehi R, Dørum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA (1998)
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group
N Engl J Med, 339 (7), 424-8
PubMed 9700175

Smith-Sørensen B, Kaern J, Holm R, Dørum A, Tropé C, Børresen-Dale AL (1998)
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
Br J Cancer, 78 (3), 375-81
PubMed 9703286

Publications 1997

Dørum A, Abeler VM, Heimdal K, Tropé C, Møller P (1997)
The problem of skipped generation and subclinical disease in familial breast-ovarian cancer
Acta Obstet Gynecol Scand, 76 (2), 166-8
PubMed 9049291

Dørum A, Møller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Tropé CG, van der Hout AH, van der Meulen MA, Buys CH, te Meerman GJ (1997)
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing
Eur J Cancer, 33 (14), 2390-2
PubMed 9616287

Publications 1996

Dørum A, Kristensen GB, Abeler VM, Tropé CG, Møller P (1996)
Early detection of familial ovarian cancer
Eur J Cancer, 32A (10), 1645-51
PubMed 8983269

Møller P, Maehle L, Heimdal K, Dørum A, Tretli S, Helgerud P, Quist H, Bjørndal H, Kåresen R, Nysted A, Varhaug JE, Fjøsne HE, Guleng RJ, Due J, Bøhler P, Giercksky KE, Tropé C, Kvinnsland S (1996)
Inherited breast carcinoma--prospective findings in 1,194 women at risk
Acta Oncol, 35 Suppl 8, 7-11
PubMed 9073043

Saetersdal A, Dørum A, Heimdal K, Helgerud P, Sager EM, Bøhler P, Tretli S, Kvinnsland S, Møller P (1996)
Inherited predisposition to breast carcinoma. Results of first round examination of 537 women at risk
Anticancer Res, 16 (4A), 1989-92
PubMed 8712731

Publications 1994

Eur. J. Cancer, 30A (10), 1470-1474

Dørum A, Kristensen GB, Tropé C (1994)
A randomised study of cisplatin versus thiotepa as induction chemotherapy in advanced ovarian carcinoma
Eur J Cancer, 30A (10), 1470-4
PubMed 7833104

Publications 1993

Dørum A, Kristensen GB, Langebrekke A, Sørnes T, Skaar O (1993)
Evaluation of endometrial thickness measured by endovaginal ultrasound in women with postmenopausal bleeding
Acta Obstet Gynecol Scand, 72 (2), 116-9
PubMed 8383406

Acta Obstet. Gynecol. Scand., 72 (8), 687

Publications 1991

Dørum A, Nesheim BI (1991)
Monochorionic monoamniotic twins--the most precarious of twin pregnancies
Acta Obstet Gynecol Scand, 70 (4-5), 381-3
PubMed 1746268